ONO 4474

Drug Profile

ONO 4474

Alternative Names: ONO-4474

Latest Information Update: 07 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Class Analgesics; Anti-inflammatories; Antirheumatics
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain

Most Recent Events

  • 09 Jan 2018 Ono Pharmaceutical terminates the MOTION phase II trial in Pain (In the elderly, In adults) in Denmark, United Kingdom, Hungary, Spain, Poland due to business reasons (PO) (NCT02997696)
  • 01 Jan 2017 Phase-II clinical trials in Pain (In the elderly, In adults) in Denmark, United Kingdom, Hungary, Spain, Poland (PO) (NCT02997696)
  • 15 Dec 2016 Ono Pharmaceutical plans the phase II MOTION trial for Pain (due to osteoarthritis of the knee, In adults, In the elderly) in United Kingdom, Denmark, Hungary, Spain and Poland (PO) (NCT02997696)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top